Description: Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care.
Home Page: www.alcon.com
ALC Technical Analysis
Chemin de Blandonnet 8
Geneva,
1214
Switzerland
Phone:
41 58 911 20 00
Officers
| Name | Title |
|---|---|
| Mr. F. Michael Ball | Exec. Chairman |
| Mr. David J. Endicott | CEO & Director |
| Mr. Arthur B. Cummings M.D. | Exec. Director |
| Mr. Timothy C. Stonesifer | Chief Financial Officer |
| Margaret Buckley | Chief Accounting Officer |
| Dr. Franck Leveiller | Sr. VP, Head of Global R&D and Chief Scientific Officer |
| Ms. Sue-Jean Lin | Sr. VP & Chief Information and Transformation Officer |
| Mr. Royce R. Bedward | Sr. VP, Gen. Counsel & Corp. Sec. |
| Mr. Laurent Attias | Head of Corp. Devel., Strategy, BD&L and M&A |
| Ms. Kimberly Martin | Sr. VP & Chief HR Officer |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| Forward PE: | 28.2486 |
|---|---|
| Trailing PE: | 62.3478 |
| Price-to-Book MRQ: | 1.7758 |
| Price-to-Sales TTM: | 3.8913 |
| IPO Date: | 2019-04-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 24000 |